{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:47:28Z","timestamp":1792162048838,"version":"4.4.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12916-2","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:02:33Z","timestamp":1792152153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision gene editing in infant neuroblastoma: a review of nanoparticle: enabled CRISPR\/Cas9 therapies"],"prefix":"10.1007","volume":"53","author":[{"given":"Samruddhi","family":"Kaknale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayush","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel V. M. V.","family":"Enoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varnitha","family":"Manikantan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"11","key":"12916_CR1","doi-asserted-by":"publisher","first-page":"e31982","DOI":"10.1002\/pbc.31982","volume":"72","author":"J Savagner","year":"2025","unstructured":"Savagner J, Munzer C, Schleiermacher G et al (2025) Neuroblastoma in infants: long-term survival from INES protocols - a SIOPEN study. Pediatr Blood Cancer 72(11):e31982. https:\/\/doi.org\/10.1002\/pbc.31982","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"12916_CR2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","volume":"27","author":"SL Cohn","year":"2009","unstructured":"Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM et al (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27(2):289\u2013297","journal-title":"J Clin Oncol"},{"issue":"23","key":"12916_CR3","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMra0804577","volume":"362","author":"JM Maris","year":"2010","unstructured":"Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202\u20132211","journal-title":"N Engl J Med"},{"issue":"6213","key":"12916_CR4","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna JA, Charpentier E (2014) The new frontier of genome engineering with CRISPR-Cas9. Science 346(6213):1258096","journal-title":"Science"},{"issue":"10","key":"12916_CR5","first-page":"a014415","volume":"3","author":"M Huang","year":"2013","unstructured":"Huang M, Weiss WA, Neuroblastoma (2013) MYCN Cold Spring Harb Perspect Med 3(10):a014415","journal-title":"MYCN Cold Spring Harb Perspect Med"},{"issue":"7215","key":"12916_CR6","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature07398","volume":"455","author":"I Janoueix-Lerosey","year":"2008","unstructured":"Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V et al (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455(7215):967\u2013970","journal-title":"Nature"},{"issue":"6121","key":"12916_CR7","first-page":"823","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE et al (2013) RNA-guided Hum genome Eng via Cas9 Sci 339(6121):823\u2013826","journal-title":"RNA-guided Hum genome Eng via Cas9 Sci"},{"key":"12916_CR8","first-page":"1003666","volume":"13","author":"C Salgado","year":"2023","unstructured":"Salgado C, Valero A, Sanchez-Hernandez S, Martin S, Valdes R, Gomez-Sanchez S et al (2023) Challenges and opportunities for CRISPR\/Cas-based gene editing in cancer cells. Front Oncol 13:1003666","journal-title":"Front Oncol"},{"key":"12916_CR9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2017.09.012","volume":"266","author":"C Liu","year":"2017","unstructured":"Liu C, Zhang L, Liu H, Cheng K (2017) Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release 266:17\u201326","journal-title":"J Control Release"},{"key":"12916_CR10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.addr.2021.02.011","volume":"172","author":"L Zhang","year":"2021","unstructured":"Zhang L, Zhang F, Yu J, Liang XJ (2021) Overcoming delivery barriers for CRISPR\/Cas9-based genome editing in solid tumours. Adv Drug Deliv Rev 172:325\u2013345","journal-title":"Adv Drug Deliv Rev"},{"issue":"40","key":"12916_CR11","doi-asserted-by":"crossref","first-page":"eabc9450","DOI":"10.1126\/sciadv.abc9450","volume":"6","author":"D Rosenblum","year":"2020","unstructured":"Rosenblum D, Gutkin A, Dammes N, Shapira A, Markovsky E, Lin L et al (2020) CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv 6(40):eabc9450","journal-title":"Sci Adv"},{"issue":"2","key":"12916_CR12","first-page":"e1964","volume":"16","author":"P Kumari","year":"2024","unstructured":"Kumari P, Singh R, Parashar P, Singh G, Singh V, Agrawal S et al (2024) Nanomedicine therapies for pediatric diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 16(2):e1964","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"12916_CR13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41427-021-00343-7","volume":"13","author":"X Luo","year":"2021","unstructured":"Luo X, Cao M, Gao F, He X (2021) Nanoparticle-mediated CRISPR\/Cas9 delivery for cancer therapy: a review of recent advances and progress. NPG Asia Mater 13:75","journal-title":"NPG Asia Mater"},{"issue":"26","key":"12916_CR14","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1038\/onc.2014.269","volume":"34","author":"K Althoff","year":"2015","unstructured":"Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprussel A et al (2015) A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene 34(26):3357\u20133368","journal-title":"Oncogene"},{"key":"12916_CR15","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/s41467-021-21247-8","volume":"12","author":"SA Hartlieb","year":"2021","unstructured":"Hartlieb SA, Sieverling L, Nadler-Holly M, Ziehm M, Toprak UH, Herrmann C et al (2021) Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. Nat Commun 12:1269","journal-title":"Nat Commun"},{"issue":"10","key":"12916_CR16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/ng.2387","volume":"44","author":"SJ Diskin","year":"2012","unstructured":"Diskin SJ, Capasso M, Schnepp RW, Cole MD, Attiyeh EF, Ji L et al (2012) Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet 44(10):1126\u20131130","journal-title":"Nat Genet"},{"issue":"1","key":"12916_CR17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.tcb.2015.07.009","volume":"26","author":"R Ceccaldi","year":"2016","unstructured":"Ceccaldi R, Rondinelli B, D\u2019Andrea AD (2016) Repair pathway choices and consequences at the double-strand break. Trends Cell Biol 26(1):52\u201364","journal-title":"Trends Cell Biol"},{"issue":"1","key":"12916_CR18","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1038\/s41467-020-18875-x","volume":"11","author":"M Martinez-Lage","year":"2020","unstructured":"Martinez-Lage M, Torres-Ruiz R, Puig-Serra P, Moreno-Gaona P, Martin MC, Moya FJ et al (2020) In vivo CRISPR\/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. Nat Commun 11(1):5060","journal-title":"Nat Commun"},{"issue":"9","key":"12916_CR19","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.neo.2019.07.007","volume":"21","author":"S Wang","year":"2019","unstructured":"Wang S, Zhang J, Wang Y, Chen M (2019) CRISPR\/Cas9-mediated MYCN deletion in neuroblastoma cells suppresses cell proliferation and tumour growth. Neoplasia 21(9):918\u2013929","journal-title":"Neoplasia"},{"issue":"5","key":"12916_CR20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nbt.3190","volume":"33","author":"T Maruyama","year":"2015","unstructured":"Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram JR, Ploegh HL (2015) Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol 33(5):538\u2013542","journal-title":"Nat Biotechnol"},{"issue":"6","key":"12916_CR21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","volume":"14","author":"YP Mosse","year":"2013","unstructured":"Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J et al (2013) Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study. Lancet Oncol 14(6):472\u2013480","journal-title":"Lancet Oncol"},{"issue":"7603","key":"12916_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR (2016) Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533(7603):420\u2013424","journal-title":"Nature"},{"issue":"12","key":"12916_CR23","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","volume":"19","author":"HA Rees","year":"2018","unstructured":"Rees HA, Liu DR (2018) Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet 19(12):770\u2013788","journal-title":"Nat Rev Genet"},{"issue":"7785","key":"12916_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM et al (2019) Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576(7785):149\u2013157","journal-title":"Nature"},{"issue":"1","key":"12916_CR25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1172\/JCI90793","volume":"128","author":"L Chen","year":"2018","unstructured":"Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS et al (2018) CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest 128(1):446\u2013462","journal-title":"J Clin Invest"},{"issue":"1","key":"12916_CR26","doi-asserted-by":"crossref","first-page":"15328","DOI":"10.1038\/s41598-018-33555-z","volume":"8","author":"Y Geng","year":"2018","unstructured":"Geng Y, Bao X, Iniguez AB, Li J, Chen Y, Pan Y et al (2018) CRISPR\/Cas9-mediated ALK knockout inhibits cell proliferation and invasion in neuroblastoma. Sci Rep 8(1):15328","journal-title":"Sci Rep"},{"issue":"2","key":"12916_CR27","first-page":"160","volume":"11","author":"YC Chou","year":"2020","unstructured":"Chou YC, Hsu WM, Yu IS, Lai FJ, Liao YF (2020) CRISPR interference-mediated MYCN repression inhibits cell growth and alters the expression of MYCN target genes in neuroblastoma cells. Cell Death Dis 11(2):160","journal-title":"Cell Death Dis"},{"issue":"6","key":"12916_CR28","first-page":"6631","volume":"9","author":"S Taghizadeh","year":"2018","unstructured":"Taghizadeh S, Kohan L, Rahimmanesh I, Ferdousmakan SA, Owrangi S, Hajigholami S et al (2018) CRISPR\/Cas9-based gene editing targeting PLAUR in human neuroblastoma cells. Oncotarget 9(6):6631\u20136641","journal-title":"Oncotarget"},{"issue":"2","key":"12916_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK et al (2019) Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med 25(2):249\u2013254","journal-title":"Nat Med"},{"issue":"5","key":"12916_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/nrg.2016.28","volume":"17","author":"SQ Tsai","year":"2016","unstructured":"Tsai SQ, Joung JK (2016) Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. Nat Rev Genet 17(5):300\u2013312","journal-title":"Nat Rev Genet"},{"issue":"1","key":"12916_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC (2017) Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 17(1):20\u201337","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"12916_CR32","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y (2021) Lipid nanoparticles for mRNA delivery. Nat Rev Mater 6(12):1078\u20131094","journal-title":"Nat Rev Mater"},{"issue":"9","key":"12916_CR33","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn JD, Smith AR, Patel MC, Shaw L, Youniss MR, van Heteren J et al (2018) A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep 22(9):2227\u20132235","journal-title":"Cell Rep"},{"issue":"4","key":"12916_CR34","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1021\/acs.chemrev.5b00367","volume":"116","author":"DA Tomalia","year":"2016","unstructured":"Tomalia DA, Khanna SN (2016) A systematic framework and nanoperiodic concept for unifying nanoscience: hard and soft nanochemistry from nanoperiodic property patterns. Chem Rev 116(4):2705\u20132774","journal-title":"Chem Rev"},{"issue":"7","key":"12916_CR35","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1039\/C2CS15261D","volume":"41","author":"YH Lee","year":"2012","unstructured":"Lee YH, Shi W, Kumar P, Liu Y, Lim B, Bhatt DL et al (2012) gold nanoparticles in biomedical applications: recent advances and perspectives. Chem Soc Rev 41(7):2656\u20132672","journal-title":"Chem Soc Rev"},{"issue":"12","key":"12916_CR36","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2967\/jnumed.116.181362","volume":"57","author":"AS Thakor","year":"2016","unstructured":"Thakor AS, Jokerst JV, Ghanouni P, Campbell JL, Mittra E, Gambhir SS (2016) Clinically approved nanoparticle imaging agents. J Nucl Med 57(12):1833\u20131837","journal-title":"J Nucl Med"},{"issue":"1","key":"12916_CR37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/molecules23010047","volume":"23","author":"M Vallet-Regi","year":"2018","unstructured":"Vallet-Regi M, Colilla M, Izquierdo-Barba I, Manzano M (2018) Mesoporous silica nanoparticles for drug delivery: current insights. Molecules 23(1):47","journal-title":"Molecules"},{"issue":"2","key":"12916_CR38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/mi.3.2.90","volume":"3","author":"WM Pardridge","year":"2003","unstructured":"Pardridge WM (2003) Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 3(2):90\u2013105","journal-title":"Mol Interv"},{"key":"12916_CR39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2015.11.032","volume":"222","author":"KB Johnsen","year":"2016","unstructured":"Johnsen KB, Moos T (2016) Revisiting nanoparticle technology for blood-brain barrier transport: unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes. J Control Release 222:32\u201346","journal-title":"J Control Release"},{"issue":"2","key":"12916_CR40","first-page":"232","volume":"1816","author":"A Bolhassani","year":"2011","unstructured":"Bolhassani A (2011) Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta 1816(2):232\u2013246","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"12916_CR41","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1148\/radiol.2202001804","volume":"220","author":"K Hynynen","year":"2001","unstructured":"Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA (2001) Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 220(3):640\u2013646","journal-title":"Radiology"},{"issue":"2","key":"12916_CR42","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr\u00e9at V (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161(2):505\u2013522","journal-title":"J Control Release"},{"issue":"41","key":"12916_CR43","doi-asserted-by":"crossref","first-page":"12029","DOI":"10.1002\/anie.201506030","volume":"54","author":"W Sun","year":"2015","unstructured":"Sun W, Ji W, Hall JM, Hu Q, Wang C, Beisel CL et al (2015) Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew Chem Int Ed Engl 54(41):12029\u201312033","journal-title":"Angew Chem Int Ed Engl"},{"issue":"11","key":"12916_CR44","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","volume":"1","author":"K Lee","year":"2017","unstructured":"Lee K, Conboy M, Park HM, Jiang F, Kim HJ, Dewitt MA et al (2017) Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng 1(11):889\u2013901","journal-title":"Nat Biomed Eng"},{"issue":"6","key":"12916_CR45","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/anie.201708689","volume":"57","author":"P Wang","year":"2018","unstructured":"Wang P, Zhang L, Zheng W, Cong L, Guo Z, Xie Y et al (2018) Thermo-triggered release of CRISPR-Cas9 system by lipid-encapsulated gold nanoparticles for tumor therapy. Angew Chem Int Ed Engl 57(6):1491\u20131496","journal-title":"Angew Chem Int Ed Engl"},{"issue":"11","key":"12916_CR46","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.addr.2008.03.012","volume":"60","author":"II Slowing","year":"2008","unstructured":"Slowing II, Vivero-Escoto JL, Wu CW, Lin VS (2008) Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 60(11):1278\u20131288","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"12916_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","volume":"19","author":"S Nooraei","year":"2021","unstructured":"Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ et al (2021) Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnol 19(1):59","journal-title":"J Nanobiotechnol"},{"issue":"2","key":"12916_CR48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","volume":"185","author":"S Banskota","year":"2022","unstructured":"Banskota S, Raguram A, Suh S, Du SW, Davis JR, Choi EH et al (2022) Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185(2):250\u2013265","journal-title":"Cell"},{"issue":"23","key":"12916_CR49","doi-asserted-by":"crossref","first-page":"e1706759","DOI":"10.1002\/adma.201706759","volume":"30","author":"RH Fang","year":"2018","unstructured":"Fang RH, Kroll AV, Gao W, Zhang L (2018) Cell membrane coating nanotechnology. Adv Mater 30(23):e1706759","journal-title":"Adv Mater"},{"issue":"27","key":"12916_CR50","doi-asserted-by":"crossref","first-page":"10980","DOI":"10.1073\/pnas.1106634108","volume":"108","author":"CM Hu","year":"2011","unstructured":"Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L (2011) Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA 108(27):10980\u201310985","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7659","key":"12916_CR51","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA et al (2017) Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546(7659):498\u2013503","journal-title":"Nature"},{"issue":"6194","key":"12916_CR52","doi-asserted-by":"crossref","first-page":"1247125","DOI":"10.1126\/science.1247125","volume":"345","author":"MA Lancaster","year":"2014","unstructured":"Lancaster MA, Knoblich JA (2014) Organogenesis in a dish: modeling development and disease using organoid technologies. Science 345(6194):1247125","journal-title":"Science"},{"issue":"3","key":"12916_CR53","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/(SICI)1097-0215(19960729)67:3<379::AID-IJC12>3.0.CO;2-3","volume":"67","author":"E Bogenmann","year":"1996","unstructured":"Bogenmann E (1996) A metastatic neuroblastoma model in SCID mice. Int J Cancer 67(3):379\u2013385","journal-title":"Int J Cancer"},{"issue":"7670","key":"12916_CR54","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature23647","volume":"549","author":"E Stewart","year":"2017","unstructured":"Stewart E, Federico SM, Chen X, Shelat AA, Bradley C, Gordon B et al (2017) Orthotopic patient-derived xenografts of paediatric solid tumours. Nature 549(7670):96\u2013100","journal-title":"Nature"},{"issue":"6","key":"12916_CR55","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM et al (2012) Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9(6):338\u2013350","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"12916_CR56","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C et al (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4(9):998\u20131013","journal-title":"Cancer Discov"},{"issue":"2\u20133","key":"12916_CR57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.yrtph.2010.03.009","volume":"57","author":"P Baldrick","year":"2010","unstructured":"Baldrick P (2010) Juvenile animal testing in drug development \u2013 is it useful? Regul Toxicol Pharmacol 57(2\u20133):291\u2013299","journal-title":"Regul Toxicol Pharmacol"},{"issue":"1","key":"12916_CR58","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nbt.3081","volume":"33","author":"JA Zuris","year":"2015","unstructured":"Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH et al (2015) Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol 33(1):73\u201380","journal-title":"Nat Biotechnol"},{"issue":"10","key":"12916_CR59","doi-asserted-by":"publisher","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","volume":"2","author":"KA Hajj","year":"2017","unstructured":"Hajj KA, Whitehead KA (2017) Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater 2(10):17056","journal-title":"Nat Rev Mater"},{"issue":"2","key":"12916_CR60","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","volume":"33","author":"SQ Tsai","year":"2015","unstructured":"Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V et al (2015) GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 33(2):187\u2013197","journal-title":"Nat Biotechnol"},{"issue":"7","key":"12916_CR61","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J (2018) CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med 24(7):927\u2013930","journal-title":"Nat Med"},{"issue":"9","key":"12916_CR62","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33(9):941\u2013951","journal-title":"Nat Biotechnol"},{"issue":"3","key":"12916_CR63","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.immuni.2017.03.009","volume":"46","author":"TR Kollmann","year":"2017","unstructured":"Kollmann TR, Kampmann B, Mazmanian SK, Marchant A, Levy O (2017) Protecting the newborn and young infant from infectious diseases: lessons from immune ontogeny. Immunity 46(3):350\u2013363","journal-title":"Immunity"},{"issue":"12","key":"12916_CR64","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157\u20131167","journal-title":"N Engl J Med"},{"issue":"1","key":"12916_CR65","first-page":"17","volume":"37","author":"A Bateman-House","year":"2023","unstructured":"Bateman-House A, Shah LD, Escandon R, McFadyen A, Hunt C (2023) Somatic gene therapy research in pediatric populations: ethical issues and guidance for operationalizing early phase trials. Pharmaceut Med 37(1):17\u201324","journal-title":"Pharmaceut Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12916-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12916-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12916-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:09:05Z","timestamp":1792159745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12916-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12916"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12916-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"4 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1725"}}